Jacquet P, Vidal-Jove J, Zhu B, Sugarbaker P
Washington Hospital Centre, Washington D.C.
Acta Chir Belg. 1994 Jul-Aug;94(4):191-7.
Peritoneal carcinomatosis represents regional spread of gastrointestinal, gynecological and other malignancies with or without evidence of systemic metastases. The authors reviewed the natural history and the different types of peritoneal carcinomatosis. A new treatment approach that combines cytoreductive surgery and intraperitoneal chemotherapy is described. The principles of this surgery and the pharmacology principles of intraperitoneal drug administration are explained. The major attraction of intraperitoneal therapy is that following intracavitary drug administration, the peritoneal cavity is exposed to higher concentrations than the rest of the body. A total of 100 patients with peritoneal carcinomatosis followed from one to ten years were treated by this approach. Patients were divided into four prognostic groups according to the histologic findings, extent of diseases, distant metastases and the completeness of cytoreductive surgery. This new cytoreductive approach is particularly effective for patients with low-grade malignancies confined to the abdominal cavity and who had a complete cytoreductive surgery.
腹膜癌病是指胃肠道、妇科及其他恶性肿瘤的区域播散，无论有无全身转移证据。作者回顾了腹膜癌病的自然病史及不同类型。描述了一种将肿瘤细胞减灭术与腹腔内化疗相结合的新治疗方法。解释了该手术的原则及腹腔内给药的药理学原理。腹腔内治疗的主要优势在于腔内给药后，腹腔所接触的药物浓度高于身体其他部位。采用该方法治疗了100例随访1至10年的腹膜癌病患者。根据组织学检查结果、疾病范围、远处转移及肿瘤细胞减灭术的彻底性，将患者分为四个预后组。这种新的肿瘤细胞减灭方法对局限于腹腔的低级别恶性肿瘤且接受了彻底肿瘤细胞减灭术的患者尤为有效。
